A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Goethe University Frankfurt · Universität Hamburg · +7 more institutions
Abstract
PURPOSE: According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used to assist in making treatment decisions after consideration of conventional markers. We developed and validated a gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer treated with adjuvant endocrine therapy. EXPERIMENTAL DESIGN: RNA levels assessed by quantitative reverse transcriptase PCR in formalin-fixed, paraffin-embedded tumor tissue were used to calculate a risk score (Endopredict, EP) consisting of eight cancer-related and three reference genes. EP was combined with nodal status and tumor…
Citation impact
- FWCI
- 10.55
- Percentile
- 100%
- References
- 18
Authors
27- MFMartin FilipitsCorresponding
Goethe University Frankfurt, Universität Hamburg, Johannes Gutenberg University Mainz, Robert Bosch Hospital, Hanusch Hospital, University Medical Center Hamburg-Eppendorf, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Siemens Healthineers (Germany), Medical University of Vienna
- MRMargaretha Rudas
Goethe University Frankfurt, Universität Hamburg, Johannes Gutenberg University Mainz, Robert Bosch Hospital, Hanusch Hospital, University Medical Center Hamburg-Eppendorf, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Siemens Healthineers (Germany), Medical University of Vienna
- RJR. Jakesz
Goethe University Frankfurt, Universität Hamburg, Johannes Gutenberg University Mainz, Robert Bosch Hospital, Hanusch Hospital, University Medical Center Hamburg-Eppendorf, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Siemens Healthineers (Germany), Medical University of Vienna
- PDPeter Dubsky
Goethe University Frankfurt, Universität Hamburg, Johannes Gutenberg University Mainz, Robert Bosch Hospital, Hanusch Hospital, University Medical Center Hamburg-Eppendorf, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Siemens Healthineers (Germany), Medical University of Vienna
- FFFlorian Fitzal
Goethe University Frankfurt, Universität Hamburg, Johannes Gutenberg University Mainz, Robert Bosch Hospital, Hanusch Hospital, University Medical Center Hamburg-Eppendorf, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Siemens Healthineers (Germany), Medical University of Vienna
Topics & keywords
- Internal medicine
- Medicine
- Breast cancer
- Oncology
- Adjuvant
- Colorectal cancer
- Cancer
- Estrogen receptor
- Good health and well-being